Stoneridge Investment Partners LLC Boosts Stock Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Stoneridge Investment Partners LLC grew its stake in shares of Chimerix, Inc. (NASDAQ:CMRX) by 22.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 44,305 shares of the biopharmaceutical company’s stock after buying an additional 8,134 shares during the period. Stoneridge Investment Partners LLC’s holdings in Chimerix were worth $154,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Valeo Financial Advisors LLC grew its holdings in shares of Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 69,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Marshall Wace LLP purchased a new position in Chimerix in the second quarter valued at about $137,000. Finally, Assenagon Asset Management S.A. raised its position in Chimerix by 154.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after purchasing an additional 496,823 shares during the period. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Stock Performance

Shares of NASDAQ CMRX opened at $4.21 on Friday. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $4.30. The stock’s 50-day simple moving average is $3.18 and its 200-day simple moving average is $1.70. The firm has a market cap of $378.65 million, a price-to-earnings ratio of -4.48 and a beta of 0.35.

Chimerix (NASDAQ:CMRX) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.26 million. During the same period in the prior year, the business posted ($0.27) EPS. As a group, research analysts predict that Chimerix, Inc. will post -0.99 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CMRX. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research report on Monday, December 30th. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a research report on Tuesday, December 10th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.